Does stomach acid really turn CBD into THC? A new review weighs the risk

Revisiting the literature on gastric CBD-to-THC conversion: contextualizing conflicting evidence.

European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences • • Review • Highly Relevant
🤖

AI Summary

Cannabidiol (CBD) is often formulated to improve its poor oral absorption, but these solubilizing products could theoretically make it more available to stomach acid. That has raised concerns that CBD might convert into tetrahydrocannabinol (THC) during digestion and cause unexpected intoxicating effects. This review revisits the conflicting evidence, focusing especially on a study that found substantial conversion in a specialized simulated gastric fluid containing the surfactant sodium dodecyl sulfate.

The authors argue that conversion requires several conditions at once: low acidity, access of CBD to that acidic environment, and stabilization of a chemical intermediate needed to form THC. They note that other laboratory studies and human data show minimal conversion, and that real stomach conditions differ from simplified laboratory models in acidity, contents, retention time, and movement. Overall, the review concludes that the risk of meaningful CBD-to-THC conversion in humans remains speculative, while recommending more targeted testing of certain micellar formulations in acidic laboratory conditions.

💡 Key Findings

1
The review concludes that meaningful CBD-to-THC conversion in humans remains speculative, despite concerns raised by some laboratory experiments.
High
80%
2
Conversion appears to require low pH, access to acidic conditions, and stabilization of a protonated carbocation intermediate involved in ring closure.
High
80%
3
Studies using other simulated gastric fluids and human data generally indicate minimal conversion, suggesting that results from SDS-modified laboratory fluid may not represent normal digestion.
Good
75%
4
The authors recommend specifically evaluating micellar CBD products containing anionic surfactants such as dodecyl sulfate under acidic simulated gastric conditions.
Good
70%

📄 Original Abstract

Preclinical and clinical studies suggest that cannabidiol (CBD) holds therapeutic promise across a range of indications. However, a major barrier to realizing CBD's full therapeutic potential is its inherently low oral bioavailability, partly due to its poor aqueous solubility. To address this, various oral delivery technologies have been explored to enhance the kinetic and apparent solubility of CBD. However, these 'solubilizing' strategies, may inadvertently increase the risk of acid-catalyzed conversion of CBD to tetrahydrocannabinol (THC) in the gastric environment. The possibility of CBD converting to THC in the acidic gastric environment has been debated for many years. Notably, the study by Merrick et al., which reported significant conversion in sodium dodecyl sulfate (SDS)-modified simulated gastric fluid (SGF), raised concerns that oral CBD products might lead to THC intoxication. Yet, other SGF-based studies and human data consistently indicate minimal conversion. We critically revisit the CBD-to-THC literature and discuss the methodological pitfalls associated with using SDS-modified SGF. We propose three conditions required for CBD-to-THC conversion: low pH, CBD accessibility to the acidic environment, and stabilization of the protonated carbocation intermediate essential for ring closure converting CBD to THC. We recommend evaluating micellar CBD formulations containing anionic surfactants like dodecyl sulfate or similar that meet these conditions in acidic SGF. We also discuss the differences between simulated and physiological gastric conditions, including pH, retention time, composition, and dynamic processes, that are likely to limit conversion risk in vivo, although detected in SGF. Overall, our literature review, comparison of human gastric conditions with in vitro SGF models, and our contextualizing of the Merrick et al. study collectively support that concerns about CBD-to-THC conversion in humans remain, at present, a speculative scenario.

Explore More Research

Stay informed about the latest cannabis science.

Your stash, decoded.